Search
Major Conference: innovation and patient access to personalised medicine
The meeting will bring together researchers, patients, physicians, regulators and politicians, to explore the current barriers and how they can be dismantled.
Read moreProfessor Degos awarded at the 17th Congress of EHA in Amsterdam
Professor Degos has made a major contribution, to our understanding of the pathogenesis and treatment of acute promyelocytic leukemia (APL), to international public health and to the EHA.
Read moreHighlights from the SWG
Joint work with the International Society on Thrombosis and Haemostasis (ISTH), the European Association for Haemophilia and Allied Disorders (EAHAD), and the European Stroke Organisation (ESO) to produce guidance on antithrombotic treatment in patients with hemophilia.
Read moreSWG Educational Activities
EHA-SWG SCIENTIFIC MEETING ON INTEGRATED CELL TRACKING IN ONCOHEMATOLOGY: DIAGNOSIS, TARGETED THERAPY AND RESIDUAL DISEASE
November 10-11, 2022 | Bordeaux, France
Meeting Chairs:
MC Béné, Nantes University
G Zini, Università Cattolica S.
Starting this November: EHA Guidelines Workshops!
EHA has initiated a series of online workshops dedicated to guidelines (produced or endorsed by EHA) for diagnosis and treatment of hematologic diseases.
Read moreAnna Vardi Physician Scientist Research Grant winner 2018
Please tell us more about yourself (name, lab, short bio)
I am Anna Vardi. I am currently working as a Consultant Hematologist at the Hematology Department and HCT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece, under the Directorship of Dr.
Press Release "Crucial Directives must be revised to protect patients' interests and improve access to treatment"
This was a key message of a two-day conference, “Haematology and the next European decade”, hosted by the European Parliament and attended by doctors, researchers, parliamentarians, patients’ organisations and Commission officials.
Read moreThe root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.
Read moreEHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders in EU is €23 billion
In Europe blood disorders affect around 80 million people. The total cost of blood disorders consists of healthcare expenditure (€15. 6 billion), productivity loss due to illness and mortality (€5. 6 billion), and the costs of informal care (€1.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- »